ZA200603174B - Novel diazaspiroalkanes and their use for treatment of CCR8 mediated diseases - Google Patents

Novel diazaspiroalkanes and their use for treatment of CCR8 mediated diseases

Info

Publication number: ZA200603174B
Authority: ZA; South Africa
Prior art keywords: treatment; mediated diseases; diazaspiroalkanes; novel; ccr8 mediated
Prior art date: 2003-10-23

Application number

ZA200603174A

Other languages

English (en)

Inventor

Bladh Hokan

Dyke Hazel Joan

Price Stephen

Van Den Heuvel Marco

Connolly Stephen

Lisius Annea

Shamovsky Igor

Original Assignee

Astrazeneca Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-10-23

Filing date

2006-04-20

Publication date

2007-03-28

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29546627&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200603174(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2006-04-20 Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab

2007-03-28 Publication of ZA200603174B publication Critical patent/ZA200603174B/xx

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Neurology (AREA)
Diabetes (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Pulmonology (AREA)
Dermatology (AREA)
Physical Education & Sports Medicine (AREA)
Cardiology (AREA)
Rheumatology (AREA)
Endocrinology (AREA)
Heart & Thoracic Surgery (AREA)
Oncology (AREA)
Orthopedic Medicine & Surgery (AREA)
Pain & Pain Management (AREA)
Virology (AREA)
Communicable Diseases (AREA)
Reproductive Health (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Hematology (AREA)
Obesity (AREA)
Tropical Medicine & Parasitology (AREA)
Psychology (AREA)
Hospice & Palliative Care (AREA)

ZA200603174A 2003-10-23 2006-04-20 Novel diazaspiroalkanes and their use for treatment of CCR8 mediated diseases ZA200603174B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
SE0302811A SE0302811D0 (sv)	2003-10-23	2003-10-23	Novel compounds

Publications (1)

Publication Number	Publication Date
ZA200603174B true ZA200603174B (en)	2007-03-28

Family

ID=29546627

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA200603174A ZA200603174B (en)	2003-10-23	2006-04-20	Novel diazaspiroalkanes and their use for treatment of CCR8 mediated diseases

Country Status (17)

Country	Link
US (1)	US20070249648A1 (xx)
EP (1)	EP1678178A1 (xx)
JP (1)	JP2007509141A (xx)
KR (1)	KR20060088557A (xx)
CN (1)	CN1898239A (xx)
AR (1)	AR046600A1 (xx)
AU (1)	AU2004284028B2 (xx)
BR (1)	BRPI0415613A (xx)
CA (1)	CA2542226A1 (xx)
IL (1)	IL174698A0 (xx)
MX (1)	MXPA06004300A (xx)
NO (1)	NO20062335L (xx)
SE (1)	SE0302811D0 (xx)
TW (1)	TW200528451A (xx)
UY (1)	UY28572A1 (xx)
WO (1)	WO2005040167A1 (xx)
ZA (1)	ZA200603174B (xx)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE0202133D0 (sv)	2002-07-08	2002-07-08	Astrazeneca Ab	Novel compounds
SE0303090D0 (sv)	2003-11-20	2003-11-20	Astrazeneca Ab	Novel compounds
SE0303541D0 (sv)	2003-12-22	2003-12-22	Astrazeneca Ab	New compounds
JP4845873B2 (ja) *	2004-03-03	2011-12-28	ケモセントリックスインコーポレーティッド	二環式および架橋した窒素複素環
JP2008534677A (ja) *	2005-04-04	2008-08-28	アストラゼネカ・アクチエボラーグ	新規ジアザスピロアルカン類およびｃｃｒ８介在疾患の処置のためのそれらの使用
EP1869044A1 (en) *	2005-04-04	2007-12-26	AstraZeneca AB	Novel diazaspiroalkanes and their use for treatment of ccr8 mediated diseases
JP2008534679A (ja) *	2005-04-04	2008-08-28	アストラゼネカ・アクチエボラーグ	新規ジアザスピロアルカン類およびｃｃｒ８介在疾患の処置のためのそれらの使用
GB0514018D0 (en) *	2005-07-07	2005-08-17	Ionix Pharmaceuticals Ltd	Chemical compounds
TW200800999A (en) *	2005-09-06	2008-01-01	Astrazeneca Ab	Novel compounds
CA2669736C (en)	2005-11-03	2017-02-21	Chembridge Research Laboratories, Inc.	Heterocyclic compounds as tyrosine kinase modulators
US20080247964A1 (en) *	2006-05-08	2008-10-09	Yuelian Xu	Substituted azaspiro derivatives
AU2007256597A1 (en) *	2006-06-09	2007-12-13	Icos Corporation	Substituted phenyl acetic acids as DP-2 antagonists
JP2009543860A (ja) *	2006-07-19	2009-12-10	アストラゼネカ・アクチエボラーグ	新規三環系スピロピペリジン化合物、それらの合成およびケモカイン受容体活性モジュレーターとしてのそれらの使用
EP2061462A2 (en) *	2006-09-15	2009-05-27	Schering Corporation	Treating pain, diabetes and lipid metabolism disorders
AU2007294771A1 (en)	2006-09-15	2008-03-20	Schering Corporation	Azetidine and azetidone derivatives useful in treating pain and disorders of lipid metabolism
CN101541795A (zh) *	2006-09-15	2009-09-23	先灵公司	用于治疗疼痛、糖尿病和脂类代谢紊乱的螺-稠合氮杂环丁烷衍生物
WO2008099165A1 (en) *	2007-02-15	2008-08-21	Astrazeneca Ab	Piperidine derivatives and their use for treatment of ccr8 mediated diseases
US8278313B2 (en)	2008-03-11	2012-10-02	Abbott Laboratories	Macrocyclic spiro pyrimidine derivatives
US8436005B2 (en)	2008-04-03	2013-05-07	Abbott Laboratories	Macrocyclic pyrimidine derivatives
WO2009151910A2 (en) *	2008-05-25	2009-12-17	Wyeth	Combination product of receptor tyrosine kinase inhibitor and fatty acid synthase inhibitor for treating cancer
WO2010141817A1 (en)	2009-06-05	2010-12-09	Janssen Pharmaceutica Nv	Heteroaryl-substituted spirocyclic diamine urea modulators of fatty acid amide hydrolase
WO2010151815A2 (en) *	2009-06-25	2010-12-29	Abbott Laboratories	3,9-diazaspiro[5,5]undecane amides and ureas and methods of use thereof
SI2547679T1 (sl)	2010-03-19	2015-12-31	Pfizer Inc.	Derivati 2,3 dihidro-1H-inden-1-il-2,7-diazaspiro(3.6)nonana in njihova uporaba kot antagonisti ali inverzni agonisti grelinskega receptorja
WO2013066718A2 (en) *	2011-10-31	2013-05-10	Merck Sharp & Dohme Corp.	Inhibitors of the renal outer medullary potassium channel
GB201122113D0 (en) *	2011-12-22	2012-02-01	Convergence Pharmaceuticals	Novel compounds
CN107569483B (zh) *	2012-06-08	2021-09-17	高等教育联邦系统-匹兹堡大学	选自苄星青霉素化合物等的化合物在制备用于治疗炎症疾病的药物中的用途
MA37756B1 (fr) *	2012-06-13	2018-09-28	Hoffmann La Roche	Nouveaux composés diazaspirocycloalcane et azaspirocycloalcane
SI2900669T1 (sl)	2012-09-25	2019-12-31	F. Hoffmann-La Roche Ag	Derivati heksahidropirolo(3,4-C)pirola in sorodne spojine kot zaviralci avtotaksina (ATX) in kot zaviralci tvorbe lizofosfatidne kisline (LPA) za zdravljenje npr. bolezni ledvic
AR095079A1 (es)	2013-03-12	2015-09-16	Hoffmann La Roche	Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo
US9227978B2 (en)	2013-03-15	2016-01-05	Araxes Pharma Llc	Covalent inhibitors of Kras G12C
WO2015048567A1 (en) *	2013-09-26	2015-04-02	Sanford-Burnham Medical Research Institute	Spirocyclic ebi2 modulators
JO3805B1 (ar)	2013-10-10	2021-01-31	Araxes Pharma Llc	مثبطات كراس جي12سي
UA118201C2 (uk)	2013-11-26	2018-12-10	Ф. Хоффманн-Ля Рош Аг	НОВИЙ ОКТАГІДРОЦИКЛОБУТА[1,2-c;3,4-c']ДИПІРОЛ-2-ІЛ
EP3119774A1 (en)	2014-03-17	2017-01-25	reMynd NV	Oxadiazole compounds
CA2937616A1 (en)	2014-03-26	2015-10-01	F. Hoffmann-La Roche Ag	Bicyclic compounds as autotaxin (atx) and lysophosphatidic acid (lpa) production inhibitors
EA032357B1 (ru)	2014-03-26	2019-05-31	Ф. Хоффманн-Ля Рош Аг	Конденсированные [1,4]диазепиновые соединения в качестве ингибиторов продукции аутотаксина (atx) и лизофосфатидиловой кислоты (lpa)
BR112017021869A2 (pt)	2015-04-10	2018-12-11	Araxes Pharma Llc	compostos quinazolina substituídos e métodos de uso dos mesmos
MA41898A (fr)	2015-04-10	2018-02-13	Hoffmann La Roche	Dérivés de quinazolinone bicyclique
AU2016304408B2 (en)	2015-07-31	2019-02-21	Pfizer Inc.,	1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as MAGL inhibitors
PE20180479A1 (es)	2015-09-04	2018-03-07	Hoffmann La Roche	Nuevos derivados de fenoximetilo
JP6845230B2 (ja)	2015-09-24	2021-03-17	エフ．ホフマン−ラロシュアーゲーＦ．Ｈｏｆｆｍａｎｎ−ＬａＲｏｃｈｅＡｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ	デュアルａｔｘ／ｃａ阻害剤としての新規な二環式化合物
EP3353178B1 (en)	2015-09-24	2021-07-14	F. Hoffmann-La Roche AG	Bicyclic compounds as dual atx/ca inhibitors
EP3353176B1 (en)	2015-09-24	2022-01-19	F. Hoffmann-La Roche AG	Bicyclic compounds as atx inhibitors
AU2016328535A1 (en)	2015-09-24	2017-11-09	F. Hoffmann-La Roche Ag	Bicyclic compounds as ATX inhibitors
WO2017058915A1 (en)	2015-09-28	2017-04-06	Araxes Pharma Llc	Inhibitors of kras g12c mutant proteins
EP3356347A1 (en)	2015-09-28	2018-08-08	Araxes Pharma LLC	Inhibitors of kras g12c mutant proteins
WO2017058728A1 (en)	2015-09-28	2017-04-06	Araxes Pharma Llc	Inhibitors of kras g12c mutant proteins
EP3356359B1 (en)	2015-09-28	2021-10-20	Araxes Pharma LLC	Inhibitors of kras g12c mutant proteins
MX2018005967A (es)	2015-11-16	2018-08-29	Araxes Pharma Llc	Compuestos de quinazolina 2-sustituida que comprenden un grupo heterociclico sustituido y metodos de uso de los mismos.
CN110382479A (zh)	2017-01-20	2019-10-25	辉瑞大药厂	作为magl抑制剂的氨基甲酸1,1,1-三氟-3-羟基丙-2-基酯衍生物
WO2018134698A1 (en)	2017-01-23	2018-07-26	Pfizer Inc.	Heterocyclic spiro compounds as magl inhibitors
EP3573954A1 (en)	2017-01-26	2019-12-04	Araxes Pharma LLC	Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
WO2018140600A1 (en)	2017-01-26	2018-08-02	Araxes Pharma Llc	Fused hetero-hetero bicyclic compounds and methods of use thereof
EP3573971A1 (en)	2017-01-26	2019-12-04	Araxes Pharma LLC	1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer
EP3573970A1 (en)	2017-01-26	2019-12-04	Araxes Pharma LLC	1-(6-(3-hydroxynaphthalen-1-yl)quinazolin-2-yl)azetidin-1-yl)prop-2-en-1-one derivatives and similar compounds as kras g12c inhibitors for the treatment of cancer
US11358959B2 (en)	2017-01-26	2022-06-14	Araxes Pharma Llc	Benzothiophene and benzothiazole compounds and methods of use thereof
CN110392679B (zh)	2017-03-16	2023-04-07	豪夫迈·罗氏有限公司	可用作双重atx/ca抑制剂的杂环化合物
JP7090099B2 (ja)	2017-03-16	2022-06-23	エフ．ホフマン－ラロシュアーゲー	Ａｔｘインヒビターとしての新規二環式化合物
CN110831933A (zh)	2017-05-25	2020-02-21	亚瑞克西斯制药公司	喹唑啉衍生物作为突变kras、hras或nras的调节剂
US10745385B2 (en)	2017-05-25	2020-08-18	Araxes Pharma Llc	Covalent inhibitors of KRAS
CN110156674A (zh) *	2018-02-13	2019-08-23	中国科学院上海有机化学研究所	一种作为吲哚胺-2,3-双加氧酶抑制剂的螺环化合物
US12134620B2 (en)	2018-08-01	2024-11-05	Araxes Pharma Llc	Heterocyclic spiro compounds and methods of use thereof for the treatment of cancer
AR116020A1 (es)	2018-09-03	2021-03-25	Bayer Ag	COMPUESTOS DE 3,9-DIAZAESPIRO[5.5]UNDECANO COMO INHIBIDORES DE GGTasa I Y SU USO PARA EL TRATAMIENTO DE ENFERMEDADES HIPERPROLIFERATIVAS
WO2020048828A1 (en)	2018-09-03	2020-03-12	Bayer Pharma Aktiengesellschaft	5-heteroaryl-3,9-diazaspiro[5.5]undecane compounds
JP7628305B2 (ja) *	2018-10-24	2025-02-10	アラクセスファーマエルエルシー	腫瘍転移を阻害するためのｇ１２ｃ変異体ｋｒａｓタンパク質の阻害剤としての２－（２－アクリロイル－２，６－ジアザスピロ［３．４］オクタン－６－イル）－６－（１ｈ－インダゾール－４－イル）－ベンゾニトリル誘導体および関連化合物
US20230038589A1 (en) *	2020-07-03	2023-02-09	Nanjing Immunophage Biotech Co., Ltd.	Methods and compositions for targeting Tregs using CCR8 inhibitors
BR112023015210A2 (pt)	2021-01-29	2023-11-07	Cedilla Therapeutics Inc	Inibidores de cdk2 e métodos de uso dos mesmos
MX2023015436A (es)	2021-06-26	2024-02-21	Cedilla Therapeutics Inc	Inhibidores de cdk2 y metodos de uso de los mismos.
CN118382436A (zh) *	2021-10-13	2024-07-23	凡况生化公司	葡糖脑苷脂酶活性的小分子调节剂及其用途
AR131211A1 (es)	2022-11-30	2025-02-26	Idorsia Pharmaceuticals Ltd	Derivados de aril- y heteroaril-sulfonamida como moduladores de ccr8

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4010201A (en) *	1974-04-12	1977-03-01	The Upjohn Company	Organic compounds
US4263317A (en) *	1979-09-06	1981-04-21	Hoechst-Roussel Pharmaceuticals, Inc.	Spiro[cyclohexane-1,1'(3'H)-isobenzofuran]s
BR9908351A (pt) *	1998-02-04	2001-11-20	Banyu Pharma Co Ltd	Compostos, processo para a preparação dosmesmos, e, composição farmacêutica
WO2003037271A2 (en) *	2001-10-30	2003-05-08	Millennium Pharmaceuticals,Inc.	Compounds, pharmaceutical compositions and methods of use therefor
SE0202133D0 (sv) *	2002-07-08	2002-07-08	Astrazeneca Ab	Novel compounds
AU2003261415C1 (en) *	2002-08-09	2010-01-14	Merck Sharp & Dohme Corp.	Tyrosine kinase inhibitors
US20070021498A1 (en) *	2004-10-14	2007-01-25	Nafizal Hossain	Novel tricyclic spiroderivatives as modulators of chemokine receptor activity

2003
- 2003-10-23 SE SE0302811A patent/SE0302811D0/xx unknown
2004
- 2004-10-21 JP JP2006536485A patent/JP2007509141A/ja active Pending
- 2004-10-21 WO PCT/SE2004/001522 patent/WO2005040167A1/en not_active Ceased
- 2004-10-21 US US10/575,525 patent/US20070249648A1/en not_active Abandoned
- 2004-10-21 CA CA002542226A patent/CA2542226A1/en not_active Abandoned
- 2004-10-21 UY UY28572A patent/UY28572A1/es unknown
- 2004-10-21 AU AU2004284028A patent/AU2004284028B2/en not_active Ceased
- 2004-10-21 KR KR1020067007682A patent/KR20060088557A/ko not_active Withdrawn
- 2004-10-21 MX MXPA06004300A patent/MXPA06004300A/es unknown
- 2004-10-21 CN CNA200480038668XA patent/CN1898239A/zh active Pending
- 2004-10-21 BR BRPI0415613-7A patent/BRPI0415613A/pt not_active IP Right Cessation
- 2004-10-21 EP EP04793824A patent/EP1678178A1/en not_active Withdrawn
- 2004-10-22 TW TW093132291A patent/TW200528451A/zh unknown
- 2004-10-22 AR ARP040103863A patent/AR046600A1/es not_active Application Discontinuation
2006
- 2006-03-30 IL IL174698A patent/IL174698A0/en unknown
- 2006-04-20 ZA ZA200603174A patent/ZA200603174B/xx unknown
- 2006-05-23 NO NO20062335A patent/NO20062335L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
BRPI0415613A (pt)	2006-12-05
AU2004284028B2 (en)	2008-03-06
NO20062335L (no)	2006-07-19
EP1678178A1 (en)	2006-07-12
SE0302811D0 (sv)	2003-10-23
JP2007509141A (ja)	2007-04-12
TW200528451A (en)	2005-09-01
AR046600A1 (es)	2005-12-14
IL174698A0 (en)	2006-08-20
KR20060088557A (ko)	2006-08-04
WO2005040167A1 (en)	2005-05-06
CA2542226A1 (en)	2005-05-06
MXPA06004300A (es)	2006-06-05
CN1898239A (zh)	2007-01-17
US20070249648A1 (en)	2007-10-25
UY28572A1 (es)	2005-05-31
AU2004284028A1 (en)	2005-05-06

Publication	Publication Date	Title
IL174698A0 (en)	2006-08-20	Novel diazaspiroalkanes and their use for treatment of ccr8 mediated diseases
IL189528A0 (en)	2008-08-07	Novel diazaspiroalkanes and their use for treatment of ccr8 mediated diseases
IL171961A0 (en)	2006-04-10	Treatment of t-cell mediated diseases
IL172346A0 (en)	2006-04-10	Treatment of t cell mediated diseases by inhibition of fgfr3
IL180600A0 (en)	2008-03-20	Compositions and methods of use for treatment of mammalian diseases
IL182643A0 (en)	2007-07-24	Novel composition and methods for the treatment of immune related diseases
EP1679058A4 (en)	2009-12-09	PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ANGIOCARDIOPATHY
AU2003268531A8 (en)	2004-03-29	Materials and methods for treatment of allergic diseases
IL162678A0 (en)	2005-11-20	N-pyrazinyl-phenylsulphonamides and their use in the treatment of chemokine mediated diseases
PL371281A1 (en)	2005-06-13	Methods and compositions for the treatment of eye diseases
ZA200700823B (en)	2008-10-29	Treatment of CCR2 mediated diseases or disorders
IL176227A0 (en)	2006-10-05	Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases
EP1753445A4 (en)	2009-05-20	TREATMENT OF EYE DISEASES AND EYE TREATMENTS WITH LANTIBIOTIC COMPOSITIONS
EP1789047A4 (en)	2010-03-17	PROCESS FOR TREATING DISEASES USING NALMEFENE AND ITS ANALOGUES
EP1773882A4 (en)	2008-09-24	DIAGNOSTICS AND THERAPEUTICS FOR DISEASES ASSOCIATED WITH SIGLEC-6
AU2003270540A8 (en)	2004-04-30	Treatment of cyclooxygenase-3 mediated diseases and disorders
AU2003270815A8 (en)	2004-04-08	Treatment of irritable bowel syndrome and related bowel diseases
HK1092464A (en)	2007-02-09	Novel diazaspiroalkanes and their use for treatment of ccr8 mediated diseases
HK1108447A (en)	2008-05-09	Novel diazaspiroalkanes and their use for treatment of ccr8 mediated diseases
HK1108449A (en)	2008-05-09	Novel diazaspiroalkanes and their use for treatment of ccr8 mediated diseases
HK1108448A (en)	2008-05-09	Novel diazaspiroalkanes and their use for treatment of ccr8 mediated diseases
HK1115882A (en)	2008-12-12	Novel diazaspiroalkanes and their use for treatment of ccr8 mediated diseases
AU2003297570A1 (en)	2004-06-18	Treatment of skin diseases
IL179209A0 (en)	2007-03-08	Small molecules for treatment of hypercholesterolemia and related diseases
HU0302933D0 (en)	2003-11-28	Treatment of diseases